Mitral Insufficiency Reduction With Biventricular Pacing

Mitral Regurgitation Clinical Trial

— MiRBi  

Official title:

Prospective.Randomized, Blinded, Crossover Chronic IDE Study of the Effects of Pacing on Mitral Regurgitation in Patients Without Standard Indications for Cardiac Resynchronization Therapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01242397
• Other study ID #: MiRBi- Acosta
• Status: Not yet recruiting
• Phase: Phase 1
• First received: November 10, 2010
• Last updated: December 1, 2010
• Start date: January 2011
• Est. completion date: January 2013

Study information

• Verified date: November 2009
• Source: Trinity Medical Center, Illinois
• Contact: Helbert Acosta, MD
• Phone: 309-236-0810
• Email: mirbiacosta[@]gmail.com
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to show that CRT(Cardiac Resynchronization Therapy) pacing in patients with severe functional MR (Mitral Regurgitation) who are not currently indicated for CRT will demonstrate chronic benefit of MR reduction( via echo measured MR/LA area and ERO per American Society of ECHO guidelines) and to show that CRT pacing is safe in these patients.

Description:

Approximately 50 patients will be randomized, followed and analyzed in this prospective study. Patients who meet all inclusion and no exclusion criteria will be enrolled and implanted with a CRT system. Baseline evaluation, which includes clinical symptom evaluation and an echocardiogram, will be performed at the time of randomization, which should occur as soon after device implant as possible but no later than 2 week post -implant. The baseline echocardiogram should be acquired prior to the device being programmed to the randomized setting. Repeat echocardiograms and scheduled follow-up evaluations will be performed at the end of each 3 month crossover period.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: January 2013
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient is at least 18 years of age

• Patients with moderate-to-severe or severe functional MR.

• EROA > 40 mm2 and an MR/LA > 40% (severe)

• 30 = EROA = 40 mm2 and 30 = MR/LA = 40% (moderate-to-severe)

• Baseline rates of 50-90 beats per minute (patients with sinus rhythm) or AF

• QRS < 120 ms

• LVEF < 35%

• Willing to sign informed consent

• On standard stable heart failure medical regimen (beta blockers and ACE-I or ARBs) for at least 1 month before randomization, if tolerated

• Patient has the ability to understand the requirements of the study, including consent for use and disclosure of research-related information

• Patient has the ability to comply with study procedures and protocol, including required study visits

Exclusion Criteria:

• candidate for CRT or has a previously implanted CRT device

• previously implanted implantable pulse generators (IPG) or implantable cardioverter defibrillator (ICD) with at least 10 % pacing in the right ventricle

• patient has life expectancy <6 months

• patient is pregnant

• significant aortic stenosis

• uncontrolled hypertension

• mitral valve stenosis

• severe mitral valve calcification

• ruptured chordae tendinae or papillary muscle

• mitral valve leaflet disorders (i.e. endocarditis, lupus, tumors, rheumatic heart disease)

• chronic mitral leaflet degeneration (ie. Marfans)

• previous valve replacement or surgery

• IV inotropes or IV vasodilators

• candidate for mitral valve repair or replacement surgery within the next 6 months

• patient has in-hospital acute coronary syndrome (ACS) (NSTEMI/STEMI) prior to randomization

• patient has planned or elective percutaneous coronary intervention (PCI) or other non-cardiac surgery prior to randomization

• patient is currently enrolled in an investigational drug or device study

• patient is clinically unstable per PI assessment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Mitral Regurgitation
• Mitral Valve Insufficiency

Intervention

Device:
• CRT pacing
The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.

Locations

Country	Name	City	State
n/a

Sponsors (5)

Lead Sponsor	Collaborator
Trinity Medical Center, Illinois	Duke University, Georgia Regents University, Massachusetts General Hospital, Medtronic

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Chronic(8 months post-implant) benefit of MR reduction	To show that CRT pacing in patients with severe functional MR who are not currently indicated for CRT will demonstrate chronic(8 months post-implant) benefit of MR reduction (via echo measured MR/LA area and ERO per American Society of Echo guidelines)	Chronic	Yes
Secondary	To compare MR Severity (ERO and MR/LA area), heart volume and dimensions via echo and clinical symptoms between two pacing modalities	Secondary objectives will compare MR severity (ERO and MR/LA area), heart volume and dimensions via echo (LA and LV), LVEF via echo (Simpson's method and clinical sypmtoms (NYHA class, QOL, 6MHW distance) between the two pacing modalities (CRT ON and OFF)	Chronic	No